A Phase II, Multicenter, Open Label Study to Evaluate the Pharmacodynamics of Nivolumab in Combination with Ipilimumab in Subjects with Advanced or Metastatic Solid Tumors

Clinical Network Services0 个研究点目标入组 21 人开始时间: 2017年7月20日最近更新: 2020年7月13日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方
入组人数: 21

研究概览研究设计入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional
分配方式: Non-randomised trial
主要目的: Treatment
盲法: Open (masking not used)

入排标准

年龄范围: 18 Years 至 o limit（—）
性别: All

入选标准

•1.Willing and able to give signed written informed consent.
•2.Male or female subjects aged > 18 years.
•3.Subjects must have a histologically or cytologically confirmed, metastatic or locally advanced solid tumor for which no standard therapy exists or standard therapy has failed.
•4.Performance status score 0-1 (Eastern Cooperative Oncology Group Scale)
•5.Estimated life expectancy > 3 months.
•6.Subjects must have pretreatment clinical laboratory values meeting the following criteria during the Screening Phase (subjects may be retested during Screening Phase):
•Adequate hematological function defined by white blood cell count (WBC) > 3 x 109/L, absolute neutrophil count (ANC) > 1.5 x 109/L, lymphocyte count > 0.5 x 109/L, platelet count > 100 x 109/L, and hemoglobin > 9 g/dL (may be transfused). For subjects with gastric cancer only, acceptable parameters for WBC, ANC, and lymphocytes are as follows: WBC > 2 x 109/L, ANC > 1.0 x 109/L, and lymphocyte count > 0.5 x 109/L.
•Adequate hepatic function based by a total bilirubin level < 1.5 x the institutional upper limit of normal (IULN), and aspartate aminotransferase (AST) level < 2.5 x IULN, and an alanine aminotransferase (ALT) level < 2.5 x IULN. For subjects with documented metastatic disease to the liver, AST and ALT levels < 5 x IULN.
•Adequate renal function defined by an estimated clearance > 50 mL/min according to Cockcroft-Gault formula or measured 24-hour creatinine clearance (or local institutional standard method).
•7.Effective contraception for both male and female subjects if risk of conception exists.
•Note: Nivolumab and ipilimumab can cause fetal harm. Thus, women of childbearing potential and men must agree to use effective contraception, defined as 2 barrier methods, or 1 barrier method with an intrauterine device or use of oral female contraceptive. Subjects must confirm use of effective contraception at least 28 days before first study drug administration and for the duration of trial participation. Female subjects will be advised to maintain effective contraception for at least 5 months after the last treatment dose. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this trial, the treating physician should be informed immediately.

排除标准

•1.Prior therapy with any antibody/drug targeting T cell co-regulatory proteins (immune checkpoints), such as anti-PD-1, anti-PD-L1, or anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) antibody.
•2.Concurrent anticancer treatment (e.g., cytoreductive therapy, radiotherapy except for palliative bone-directed radiotherapy, immune therapy, or cytokine therapy except for erythropoietin) within 21 days or 5x (five times) their half-lives (whichever is shorter) before the first dose of trial treatment; major surgery within 28 days before start of trial treatment (excluding prior diagnostic biopsy); or use of hormonal agents within 7 days before start of trial treatment, except for subjects with castration-resistant prostate cancer (CRPC), who may remain on treatment with luteinizing hormone–releasing hormone agonists or antagonists.
•Note: Subjects receiving bisphosphonate or denosumab are eligible provided that treatment was initiated equal to 14 days before first dose of treatment.
•3.Use of any investigational drug within 21 days or 5x their half-lives (whichever is shorter) before the first dose of trial treatment.
•4.Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs 14 days before initiation of trial treatment. Steroids with no or minimal systemic effect (topical, inhalation) are allowed.
•Note: Use of inhaled or topical corticosteroid is permitted.
•Note: Steroid pre-medication for radiographic imaging for dye allergies is permitted.
•5.Rapidly progressive disease.
•6.Active central nervous system metastases.
•7.Receipt of any organ transplantation, including allogeneic stem-cell transplantation.
•8.Significant acute or chronic infections, including:
•Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS).
•Positive test for hepatitis B virus (HBV) surface antigen and/or confirmatory hepatitis C virus (HCV) RNA (if anti-HCV antibody tested positive).
•9.Active or history of any autoimmune disease (subjects with diabetes type 1, vitiligo, psoriasis, hypo-, or hyperthyroid disease not requiring immunosuppressive treatment are eligible) or immunodeficiencies.
•10.Known severe hypersensitivity reactions to monoclonal antibodies (NCI CTCAE grade equal to 3), any history of anaphylaxis, or uncontrolled asthma (i.e., equal to 3 features of partly controlled asthma).
•11.Persisting toxicity related to prior therapy of NCI CTCAE grade greater than 1 severity. Sensory neuropathy of grade 2 is acceptable.
•12.Pregnancy or breast feeding.
•13.Known alcohol or drug abuse.
•14.Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (less than 6 months before enrollment), myocardial infarction (less than 6 months before enrollment), unstable angina, congestive heart failure (New York Heart Association class is equal to II), or serious uncontrolled cardiac arrhythmia requiring medication.
•15.All other significant diseases (e.g., inflammatory bowel disease) that, in the opinion of the investigator, might impair the subject’s tolerance of trial treatment.
•16.Any psychiatric condition that would prohibit understanding or rendering of informed consent.
•17.Legal incapacity or limited legal capacity.
•18.Vaccination within 4 weeks of first dose of the combination nivolumab/ipilimumab and while on study except for administration of inactivated vaccines (e.g., inactiv

研究者

发起方

Clinical Network Services

相似试验

终止

2 期

Phase II Study of CUV1647 in Erythropoietic Protoporphyria (EPP)Erythropoietic Protoporphyria (EPP)Human Genetics and Inherited Disorders - Other metabolic and endocrine disorders

ACTRN12606000535572Clinuvel Pharmaceuticals10

进行中（未招募）

1 期

EUCTR2020-002368-30-FRAstraZeneca AB100

招募中

2 期

A clinical trial to evaluate the efficacy and safety of Trastuzumab Deruxtecan in treating patients with HER2 positive Solid Tumors

CTRI/2021/03/031930AstraZeneca AB

进行中（未招募）

1 期

A study to investigate anti-tumor activity and safety of trastuzumab deruxtecan in patients with solid tumors carrying specific HER2 mutations.Treatment of unresectable and/or metastatic solid tumors harboring specific HER2 activating mutations regardless of tumor histology.MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)

EUCTR2020-002368-30-DKAstraZeneca AB100

进行中（未招募）

1 期

EUCTR2020-002368-30-ITASTRAZENECA AB100